The University of Arizona
Map Home
Loading...
Adjust height of sidebar
KMap

Grant

A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator's Choice in Previously Untreated

Active
$7.5M Funding
3 People
External

Related Topics

People